Loading...

Biofrontera Inc.

BFRIWNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.11
$0.02(16.91%)

Biofrontera Inc. (BFRIW) Stock Overview

Explore Biofrontera Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 60.1/100

Key Financials

Market Cap6.7M
P/E Ratio-0.53
EPS (TTM)$-1.30
ROE-2.16%
Fundamental Analysis

AI Price Forecasts

1 Week$0.11
1 Month$0.08
3 Months$0.01
1 Year Target$0.01

BFRIW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Biofrontera Inc. (BFRIW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.01.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.53 and a market capitalization of 6.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for BFRIWStats details for BFRIW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for BFRIWAnalyst Recommendations details for BFRIW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

CEO

Hermann Luebbert

Employees

92

Headquarters

120 Presidential Way, Woburn, DE

Founded

1970

Frequently Asked Questions

;